Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Sep;26(3):285–293. doi: 10.1111/j.1365-2125.1988.tb05279.x

Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.

J H Jonkman 1, L Borgström 1, W J van der Boon 1, O E de Noord 1
PMCID: PMC1386541  PMID: 3179168

Abstract

1. The pharmacokinetic interaction of terbutaline and theophylline and chronopharmacokinetics of both drugs were studied in a three-way crossover study with repeated administration of terbutaline (Bricanyl Depot) 7.5 mg twice daily, theophylline (Theo-Dur) 300 mg twice daily alone or the combination of both for 7 days to 12 healthy volunteers (six male and six female). 2. After the morning dose on day 7, blood and urine were sampled for 12 h, and after the evening dose on day 7, blood and urine were sampled for 48 h. Theophylline concentrations in plasma and concentrations of unchanged drug and metabolites in urine were determined by two selective high performance liquid chromatography methods. Terbutaline concentrations in plasma and urine were measured with a gas chromatography-mass spectrometry method. Area under the plasma concentration-time curve, fluctuations in plasma concentration, mean residence time, elimination half-life, renal clearance as well as maximal, minimal and average plasma concentration at steady state were evaluated. 3. The addition of terbutaline to the repeated administration of theophylline lowered the relative bioavailability of theophylline by approximately 11% during the night interval. The rate of elimination of theophylline and mean residence time were influenced accordingly. No significant changes in excretion of the theophylline metabolites were observed, but the excretion of 3-methylxanthine was slightly reduced by the concomitant terbutaline administration. None of the observed changes should be of any clinical importance. 4. The addition of theophylline did not influence any of the calculated pharmacokinetic parameters of terbutaline. 5. It can be concluded that no dosage adjustment is necessary when terbutaline and theophylline are given together.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
285

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baadsgaard O., Oberg B., Thomsen L., Klitgaard N., Simonsen E. Bronchodilator effects of terbutaline and theophylline alone and in combination in patients with chronic obstructive lung disease. Allergol Immunopathol (Madr) 1985 Nov-Dec;13(6):471–474. [PubMed] [Google Scholar]
  2. Birkett D. J., Dahlqvist R., Miners J. O., Lelo A., Billing B. Comparison of theophylline and theobromine metabolism in man. Drug Metab Dispos. 1985 Nov-Dec;13(6):725–728. [PubMed] [Google Scholar]
  3. CORNISH H. H., CHRISTMAN A. A. A study of the metabolism of theobromine, theophylline, and caffeine in man. J Biol Chem. 1957 Sep;228(1):315–323. [PubMed] [Google Scholar]
  4. Danziger Y., Garty M., Volwitz B., Ilfeld D., Varsano I., Rosenfeld J. B. Reduction of serum theophylline levels by terbutaline in children with asthma. Clin Pharmacol Ther. 1985 Apr;37(4):469–471. doi: 10.1038/clpt.1985.73. [DOI] [PubMed] [Google Scholar]
  5. Davis S. S., Hardy J. G., Fara J. W. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986 Aug;27(8):886–892. doi: 10.1136/gut.27.8.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Grygiel J. J., Wing L. M., Farkas J., Birkett D. J. Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther. 1979 Nov;26(5):660–667. doi: 10.1002/cpt1979265660. [DOI] [PubMed] [Google Scholar]
  7. Hemstreet M. P., Miles M. V., Rutland R. O. Effect of intravenous isoproterenol on theophylline kinetics. J Allergy Clin Immunol. 1982 Apr;69(4):360–364. doi: 10.1016/0091-6749(82)90146-4. [DOI] [PubMed] [Google Scholar]
  8. Jenne J. W., Nagasawa H. T., Thompson R. D. Relationship of urinary metabolites of theophylline to serum theophylline levels. Clin Pharmacol Ther. 1976 Mar;19(3):375–381. doi: 10.1002/cpt1976193375. [DOI] [PubMed] [Google Scholar]
  9. Jonkman J. H., Tang D., Upton R. A., Riegelman S. Measurement of excretion characteristics of theophylline and its major metabolites. Eur J Clin Pharmacol. 1981;20(6):435–441. doi: 10.1007/BF00542096. [DOI] [PubMed] [Google Scholar]
  10. Jonkman J. H. Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):736–742. doi: 10.1016/0091-6749(86)90054-0. [DOI] [PubMed] [Google Scholar]
  11. Jonkman J. H., Upton R. A. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet. 1984 Jul-Aug;9(4):309–334. doi: 10.2165/00003088-198409040-00002. [DOI] [PubMed] [Google Scholar]
  12. Jonkman J. H., van der Boon W. J., Balant L. P., Schoenmaker R., Holtkamp A. Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults. Eur J Clin Pharmacol. 1984;26(2):215–222. doi: 10.1007/BF00630288. [DOI] [PubMed] [Google Scholar]
  13. Lohmann S. M., Miech R. P. Theophylline metabolism by the rat liver microsomal system. J Pharmacol Exp Ther. 1976 Jan;196(1):213–225. [PubMed] [Google Scholar]
  14. Lönnerholm G., Foucard T., Lindström B. Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma. Br Med J (Clin Res Ed) 1981 Mar 28;282(6269):1029–1031. doi: 10.1136/bmj.282.6269.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Muir K. T., Jonkman J. H., Tang D. S., Kunitani M., Riegelman S. Simultaneous determinations by theophylline and its major metabolites in urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr. 1980 Nov 14;221(1):85–95. doi: 10.1016/s0378-4347(00)81010-5. [DOI] [PubMed] [Google Scholar]
  16. Nicklas R. A., Balazs T. Adverse effects of theophylline-beta agonist interactions. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):806–811. doi: 10.1016/0091-6749(86)90065-5. [DOI] [PubMed] [Google Scholar]
  17. Nyberg L. Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis Suppl. 1984;134:149–160. [PubMed] [Google Scholar]
  18. Pfeffer M. Estimation of mean residence time from data obtained when multiple-dosing steady state has been reached. J Pharm Sci. 1984 Jun;73(6):854–856. doi: 10.1002/jps.2600730645. [DOI] [PubMed] [Google Scholar]
  19. Smith S. R., Kendall M. J. Potentiation of the adverse effects of intravenous terbutaline by oral theophylline. Br J Clin Pharmacol. 1986 Apr;21(4):451–453. doi: 10.1111/j.1365-2125.1986.tb05221.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Snidow J., Stephens M., Self T., Stewart C., Bobo L., Pieper J. A. Acute effects of short-term subcutaneous terbutaline on theophylline disposition. Eur J Clin Pharmacol. 1987;32(2):191–193. doi: 10.1007/BF00542194. [DOI] [PubMed] [Google Scholar]
  21. Tang-Liu D. D., Williams R. L., Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther. 1982 Mar;31(3):358–369. doi: 10.1038/clpt.1982.46. [DOI] [PubMed] [Google Scholar]
  22. Vandewalker M. L., Kray K. T., Weber R. W., Nelson H. S. Addition of terbutaline to optimal theophylline therapy. Double blind crossover study in asthmatic patients. Chest. 1986 Aug;90(2):198–203. doi: 10.1378/chest.90.2.198. [DOI] [PubMed] [Google Scholar]
  23. Wilson J. D., Sutherland D. C., Thomas A. C. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet. 1981 Jun 6;1(8232):1235–1237. doi: 10.1016/s0140-6736(81)92403-x. [DOI] [PubMed] [Google Scholar]
  24. Wolfe J. D., Tashkin D. P., Calvarese B., Simmons M. Bronchodilator effects of terbutaline and aminophylline alone and in combination in asthmatic patients. N Engl J Med. 1978 Feb 16;298(7):363–367. doi: 10.1056/NEJM197802162980703. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES